Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

US Department of Health and Human Services

- PMLiVE

2017 pharma trends: Bon chance!

A US take on the power shift in Washington and what it could mean for the industry

- PMLiVE

Pharma ‘getting away with murder’, says Trump

Almost $25bn wiped off big pharma stocks as US President-elect turns attention to drug pricing

Biogen Idec building

FDA approves Biogen’s Spinraza for spinal muscular atrophy

Analysts predict blockbuster sales as drug is priced at $750,000 for first year of treatment

- PMLiVE

Making a list and checking it twice…

The promise of mobile health lies not in recording information but in promoting behaviour change

- PMLiVE

Global drug spending will rise by a third to $1.5trn in 2021

However, rate of growth will not match previous years due to pricing and access pressures

- PMLiVE

Pfizer gets record £84m fine for hiking price of epilepsy drug

US firm plans to appeal after CMA finds it raised NHS fee by 2,600% in 2012

- PMLiVE

Ono faces steep price cut for Opdivo in Japan

Japanese regulator proposes 50% cut after drug’s population growth exceeds initial projections

- PMLiVE

Mylan facing US anticompetitive practice probe

Senate judiciary committee calls for fair competition review over EpiPen sales

Pricing’s dodos

Mylan isn’t alone in its outdated practices

Bristol-Myers Squibb (BMS) building

NICE U-turn on Opdivo for kidney cancer

BMS sways the watchdog with new data and a patient access scheme

EU flag

Italian pharma scandals prompts call for EU-wide pricing probe

Aspen fined €5.2m for threat to halt supply of cancer drugs if price hikes not accepted

- PMLiVE

EpiDemic

Getting serious about drug pricing

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links